ITGAX

Chr 16

integrin subunit alpha X

Also known as: CD11C, SLEB6

The integrin alpha X chain protein combines with the beta 2 chain to form a leukocyte-specific integrin (CR4) that mediates monocyte and neutrophil adhesion to endothelium and facilitates phagocytosis of complement-coated particles and erythrocytes. This gene is extremely intolerant to loss-of-function variants (pLI near 1.0), but no established Mendelian diseases have been reported from ITGAX mutations. Clinical phenotypes, if they exist, would likely involve immune dysfunction affecting leukocyte trafficking and inflammatory responses.

OMIMResearchSummary from RefSeq, UniProt
MultiplemechanismLOEUF 0.72
Clinical SummaryITGAX
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
9 unique Pathogenic / Likely Pathogenic· 163 VUS of 238 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.72LOEUF
pLI 0.000
Z-score 3.39
OE 0.54 (0.410.72)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
0.55Z-score
OE missense 0.94 (0.881.00)
658 obs / 699.2 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.54 (0.410.72)
00.351.4
Missense OE0.94 (0.881.00)
00.61.4
Synonymous OE1.05
01.21.6
LoF obs/exp: 35 / 64.4Missense obs/exp: 658 / 699.2Syn Z: -0.69
DN
0.74top 25%
GOF
0.7127th %ile
LOF
0.2387th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median
GOFprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

238 submitted variants in ClinVar

Classification Summary

Pathogenic8
Likely Pathogenic1
VUS163
Likely Benign23
Benign3
8
Pathogenic
1
Likely Pathogenic
163
VUS
23
Likely Benign
3
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
8
0
8
Likely Pathogenic
0
0
1
0
1
VUS
0
156
7
0
163
Likely Benign
0
17
0
6
23
Benign
0
2
0
1
3
Total0175167198

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

ITGAX · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →